GOSS

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Pulmonary hypertension, Health care, Artificial intelligence, American Thoracic Society, Whitehead Institute, Lung transplantation, Idiopathic pulmonary fibrosis, Medical director, Biomedical Research, Pulmonology, Capital Group Companies, Gossamer, Partnership, American College, Wellesley College, American studies, Commerce, Creative, Medical education, Biomedicine, Latin American studies, International Society, Putnam Investments, MNTN, University, Senior, House, Publication, Portfolio manager, FDA, Internal medicine, Entrepreneurship, Lord Abbett, MIT, Capital, Bloomberg, GOSS, Orthostatic hypertension, IPF, Initial public offering, Partner, Idiopathic disease, PAH, Pharmaceutical industry

Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.

Key Points: 
  • Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.
  • Ms. Drynan joins the Board with an extensive background in finance, investment, and entrepreneurship, specializing in the biotechnology industry.
  • “The addition of Dr. Nathan to our Board signifies a pivotal moment in Gossamer’s evolution,” said Faheem Hasnain, Co-Founder, Chairman and CEO of Gossamer Bio.
  • Ms. Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., which she founded in 2016.

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Pharmaceutical, Health, Cardiology, GOSS, Research, New Drug Application, Research and development, Marketing, Security (finance), Functional, Pulmonary hypertension, Entrepreneurship, PAH, PMDA, Administration, Gossamer, Patient, Public expenditure, Clinical trial, Medication, Orthostatic hypertension, G&A, Pharmaceutical industry

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update.
  • “This advancement marks a significant milestone in Gossamer’s journey, and it was made possible due to the tireless efforts of the Gossamer team.
  • Topline results from the PROSERA Study are expected in the fourth quarter of 2025.
  • Financial Results for Quarter and Full Year Ended December 31, 2023
    Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of December 31, 2023, were $296.4 million.

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, January 8, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, GOSS, Gossamer, Compensated emancipation, Orthostatic hypertension, Employment, PAH

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective January 5, 2024, to two new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 212,500 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”).

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective January 5, 2024, to two new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 212,500 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”).
  • The awards were granted as an inducement material to the employees entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $0.85 per share, which is equal to the closing price of Gossamer’s common stock as reported by The Nasdaq Global Select Market on January 5, 2024.
  • The options are subject to the terms and conditions of the 2023 Inducement Plan and the terms and conditions of a stock option agreement covering the grants.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Gossamer Bio, Inc. (NASDAQ: GOSS) and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, November 11, 2023
Acquisition, GOSS, Gossamer

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Gossamer Bio, Inc. (NASDAQ: GOSS) on behalf of the company’s investors.

Key Points: 
  • PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Gossamer Bio, Inc. (NASDAQ: GOSS) on behalf of the company’s investors.
  • Gossamer stockholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.
  • Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis.
  • For additional information about Kaskela Law LLC please visit www.kaskelalaw.com .

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Webcast, PAH, Patient, GOSS, Pulmonary hypertension, Orthostatic hypertension, CSF1R

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it will host a public conference call and webcast for investors and analysts on Monday, December 18, 2023 at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it will host a public conference call and webcast for investors and analysts on Monday, December 18, 2023 at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients.
  • Seralutinib is a tyrosine kinase inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, specifically designed to be delivered via dry powder inhaler for the treatment of pulmonary hypertension.
  • The live audio webcast may be accessed through the “Events / Presentations” page in the “Investors” section of the Company's website at www.gossamerbio.com .
  • Alternatively, the conference call may be accessed through the following:
    A replay of the audio webcast will be available for 30 days on the “Investors” section of the Company's website, www.gossamerbio.com .

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, December 5, 2023
Health, Clinical Trials, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Gossamer, PAH, Employment, GOSS, Compensated emancipation, Orthostatic hypertension, Pharmaceutical industry

The Compensation Committee of Gossamer’s Board of Directors approved the grant, effective December 4, 2023, to Mr. Smith of a stock option to purchase 1,500,000 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”).

Key Points: 
  • The Compensation Committee of Gossamer’s Board of Directors approved the grant, effective December 4, 2023, to Mr. Smith of a stock option to purchase 1,500,000 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”).
  • The award was granted as an inducement material to Mr. Smith entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $0.969 per share, which is equal to the closing price of Gossamer Bio’s common stock as reported by The Nasdaq Global Select Market on December 4, 2023.
  • The options are subject to the terms and conditions of the 2023 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Retrieved on: 
Tuesday, December 5, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Texas A&M University, Johnson & Johnson, Senior, GOSS, Entrepreneurship, Gossamer, Patient, Pulmonary hypertension, Bristol Myers Squibb, Orthostatic hypertension, Marketing, Merck, Nuvelo, PAH, Pharmaceutical industry, Actelion

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Bob Smith as its Chief Commercial Officer.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Bob Smith as its Chief Commercial Officer.
  • “We are proud to welcome Bob Smith to the Gossamer team and his 30 years of expertise at this critical time in our company’s history,” said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio.
  • “With Bob’s arrival, Gossamer is well-positioned to transition itself from a pre-commercial, clinical-stage biotechnology company to a fully integrated commercial organization focused on bringing seralutinib to patients with pulmonary hypertension.
  • As the principal sales leader, Mr. Smith managed all U.S. sales operations, including sales, training, sales operations, patient & professional advocacy, key customer engagement and territory management.

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

Retrieved on: 
Wednesday, November 29, 2023
Research, Legal, Finance, Clinical Trials, Professional Services, Biotechnology, General Health, Pharmaceutical, Health, Science, Merck & Co., Acquisition, Ropes & Gray, General counsel, GOSS, Entrepreneurship, Executive, Gossamer, Pulmonary hypertension, Doctor of Philosophy, Bristol Myers Squibb, Orthostatic hypertension, Merck, Stanford University, Harvard College, Acceleron Pharma, Massachusetts Institute of Technology, Harvard Law School, Corporate development, PAH, Biology, Pharmaceutical industry, Management, Acceleron

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors.
  • “Today, we are thrilled to announce that Dr. John Quisel has joined the Gossamer team," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio.
  • We are confident that Dr. Quisel’s appointment enhances our ability to get seralutinib to patients.”
    “I am honored to join Gossamer’s Board at this pivotal moment for the Company,” said Dr. Quisel.
  • During his tenure, Dr. Quisel also served in various roles, including Senior Vice President of Corporate Development and General Counsel.

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Research, Research and development, Stanford University, Bio, III, Public expenditure, G&A, Functional, Orthostatic hypertension, Entrepreneurship, R, Gossamer, Critical Care Medicine (journal), GOSS, FRI, Security (finance), PAH, Site, Patient, Administration, Pharmaceutical industry

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.
  • “Additionally, we were excited to have presented the results from the Phase 2 TORREY lung imaging sub-study presented at the European Respiratory Society International Congress 2023.
  • Gossamer expects to release further TORREY OLE data from the ongoing extension study in PAH patients in the fourth quarter of 2023.
  • Financial Results for Quarter Ended September 30, 2023
    Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of September 30, 2023, were $328.9 million.

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Gossamer Bio, Inc.; Urges Gossamer Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

Retrieved on: 
Thursday, November 2, 2023
GOSS, Gossamer

STAMFORD, Conn., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Gossamer Bio, Inc. (Nasdaq: GOSS) (“Gossamer” or the “Company”) on behalf of the Company’s investors.

Key Points: 
  • STAMFORD, Conn., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Gossamer Bio, Inc. (Nasdaq: GOSS) (“Gossamer” or the “Company”) on behalf of the Company’s investors.
  • Gossamer stockholders are encouraged to contact Abbott Cooper PLLC by calling (475) 333-0674, emailing [email protected] or visiting our website at www.abbottlawyer.com for additional information about this investigation as well as their legal rights and options.
  • Abbott Cooper PLLC is dedicated to shareholders’ rights and empowering shareholders through strategic counsel and legal advocacy.
  • For additional information about Abbott Cooper PLLC, please visit www.abbottlawyer.com .